Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Rhythm Pharmaceuticals Inc's Business Segments
Rhythm Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Single Reportable
Total Revenue
$ 71
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Single Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable | $ 71 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Product100%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 71 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of certain rare genetic disorders of obesity. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
The primary focus of Rhythm Pharmaceuticals is on developing drugs that target pathways in the gut-brain axis, which plays a crucial role in regulating metabolism and energy balance. By targeting these pathways, the company aims to provide novel treatment options for patients with certain rare genetic disorders of obesity, such as Prader-Willi syndrome (PWS) and others.
Prader-Willi syndrome is a complex genetic disorder characterized by excessive hunger, obesity, and other medical and behavioral symptoms. It is caused by the loss of function of certain genes on chromosome 15. Rhythm Pharmaceuticals aims to address the underlying cause of PWS by developing therapies that target the melanocortin-4 receptor (MC4R) pathway, which is believed to be a key driver of the hyperphagia (excessive hunger) and obesity seen in individuals with PWS.
The company's most advanced drug candidate is setmelanotide, a novel peptide agonist of the MC4R pathway. Setmelanotide has shown promising results in clinical trials, with significant reductions in excessive hunger and weight loss observed in patients with PWS. Rhythm Pharmaceuticals has also initiated clinical trials to evaluate the potential of setmelanotide in other rare genetic disorders of obesity, such as Alström syndrome.
In addition to its drug development efforts, Rhythm Pharmaceuticals is also focused on building a comprehensive patient-centric support network to provide education, resources, and support to patients and their families living with rare genetic disorders of obesity. The company aims to create a holistic approach to patient care and ensure that its therapies are accessible and affordable for those who need them.
Rhythm Pharmaceuticals has a team of experienced scientists, physicians, and industry professionals who are dedicated to advancing the understanding and treatment of rare genetic disorders of obesity. The company has established collaborations with academic institutions, patient advocacy groups, and regulatory agencies to accelerate the development and commercialization of its therapies.
Overall, Rhythm Pharmaceuticals Inc. is committed to improving the lives of patients with rare genetic disorders of obesity through the development of innovative therapies that target the underlying causes of these conditions. The company's focus on the gut-brain axis and the MC4R pathway, along with its patient-centric approach, positions it as a leader in the field of obesity therapeutics.
The primary focus of Rhythm Pharmaceuticals is on developing drugs that target pathways in the gut-brain axis, which plays a crucial role in regulating metabolism and energy balance. By targeting these pathways, the company aims to provide novel treatment options for patients with certain rare genetic disorders of obesity, such as Prader-Willi syndrome (PWS) and others.
Prader-Willi syndrome is a complex genetic disorder characterized by excessive hunger, obesity, and other medical and behavioral symptoms. It is caused by the loss of function of certain genes on chromosome 15. Rhythm Pharmaceuticals aims to address the underlying cause of PWS by developing therapies that target the melanocortin-4 receptor (MC4R) pathway, which is believed to be a key driver of the hyperphagia (excessive hunger) and obesity seen in individuals with PWS.
The company's most advanced drug candidate is setmelanotide, a novel peptide agonist of the MC4R pathway. Setmelanotide has shown promising results in clinical trials, with significant reductions in excessive hunger and weight loss observed in patients with PWS. Rhythm Pharmaceuticals has also initiated clinical trials to evaluate the potential of setmelanotide in other rare genetic disorders of obesity, such as Alström syndrome.
In addition to its drug development efforts, Rhythm Pharmaceuticals is also focused on building a comprehensive patient-centric support network to provide education, resources, and support to patients and their families living with rare genetic disorders of obesity. The company aims to create a holistic approach to patient care and ensure that its therapies are accessible and affordable for those who need them.
Rhythm Pharmaceuticals has a team of experienced scientists, physicians, and industry professionals who are dedicated to advancing the understanding and treatment of rare genetic disorders of obesity. The company has established collaborations with academic institutions, patient advocacy groups, and regulatory agencies to accelerate the development and commercialization of its therapies.
Overall, Rhythm Pharmaceuticals Inc. is committed to improving the lives of patients with rare genetic disorders of obesity through the development of innovative therapies that target the underlying causes of these conditions. The company's focus on the gut-brain axis and the MC4R pathway, along with its patient-centric approach, positions it as a leader in the field of obesity therapeutics.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for rare genetic disorders of obesity. Its primary focus is on advancing therapies that target metabolic and endocrine systems to address the unmet needs of individuals with these conditions. Here’s an extensive overview of the companys segments, products, and services:
Therapeutic Segments
1. Rare Genetic Disorders of Obesity:
- Rhythm Pharmaceuticals primarily concentrates on developing treatments for rare forms of obesity, particularly those caused by genetic mutations. These conditions often lead to significant physical, emotional, and economic burdens for affected individuals and their families. The segment targets disorders like Bardet-Biedl Syndrome and Leydig Cell Hypoplasia.
2. Endocrine and Metabolic Disorders:
- The company also explores therapies for broader endocrine and metabolic conditions that might not fall strictly within the genetic disorders of obesity. These therapies focus on the regulatory pathways of appetite and energy balance.
Key Products
1. Setmelanotide (Imcivree):
- Indication: This is Rhythm’s flagship product, recently approved for chronic weight management in patients aged 6 years and older with obesity due to one of several specific genetic disorders, including POMC, LEPR, and MC4R deficiencies.
- Mechanism of Action: Setmelanotide is a melanocortin-4 receptor (MC4R) agonist. By targeting the hypothalamic pathways that regulate appetite, it aims to restore balance in energy homeostasis and promote weight loss.
- Clinical Trials: Multiple pivotal trials have provided evidence of sustained weight loss and improved metabolic parameters in patients, thereby reinforcing the products efficacy and safety profile.
2. Pipeline Developments:
- Rhythm is continuously expanding its pipeline to include other therapies targeting additional genetic obesity disorders. This includes investigational therapies in various stages of clinical trials aimed at different genetic targets.
Services
1. Patient Support Programs:
- Rhythm provides robust patient support services to help individuals navigate their treatment journey. These programs may include:
- Access Support: Helping patients understand their insurance benefits and access medication through financial assistance programs.
- Treatment Education: Offering educational resources for patients and healthcare providers about the use of Setmelanotide and its effects.
- Monitoring & Follow-up: Regular check-ins to monitor patient progress, potential side effects, and adherence to therapy.
2. Collaborations and Partnerships:
- The company may engage in collaborations with academic institutions, research organizations, and healthcare providers to further clinical research and improve treatment methodologies for rare genetic disorders.
3. Advocacy and Awareness:
- Rhythm actively participates in raising awareness about rare genetic disorders of obesity. They may collaborate with patient advocacy groups to ensure that those affected by these conditions have a voice in the research and development process.
Research and Development
- Rhythm invests significantly in research and development to explore new therapeutic approaches and enhance the understanding of the underlying mechanisms of obesity-related genetic disorders. This includes:
- Preclinical Studies: Investigating potential new compounds and their effects on various pathways involved in metabolism and energy balance.
- Clinical Research: Conducting Phase 1, 2, and 3 clinical trials to evaluate safety, efficacy, and long-term outcomes for existing and new therapies.
Market Position
- The company is positioned within a niche market focusing on rare genetic disorders, which sets it apart from traditional pharmaceutical companies that target broader therapeutic areas. The specialized nature of the market means Rhythm can address specific patient needs with tailored approaches.
Summary
Rhythm Pharmaceuticals, Inc. is at the forefront of addressing the complexities of rare genetic disorders of obesity through focused therapeutic development. With its flagship product Setmelanotide and an expanding pipeline, the company aims to meet the significant unmet needs of affected patients while providing comprehensive support services designed to improve patient experiences and outcomes.
Therapeutic Segments
1. Rare Genetic Disorders of Obesity:
- Rhythm Pharmaceuticals primarily concentrates on developing treatments for rare forms of obesity, particularly those caused by genetic mutations. These conditions often lead to significant physical, emotional, and economic burdens for affected individuals and their families. The segment targets disorders like Bardet-Biedl Syndrome and Leydig Cell Hypoplasia.
2. Endocrine and Metabolic Disorders:
- The company also explores therapies for broader endocrine and metabolic conditions that might not fall strictly within the genetic disorders of obesity. These therapies focus on the regulatory pathways of appetite and energy balance.
Key Products
1. Setmelanotide (Imcivree):
- Indication: This is Rhythm’s flagship product, recently approved for chronic weight management in patients aged 6 years and older with obesity due to one of several specific genetic disorders, including POMC, LEPR, and MC4R deficiencies.
- Mechanism of Action: Setmelanotide is a melanocortin-4 receptor (MC4R) agonist. By targeting the hypothalamic pathways that regulate appetite, it aims to restore balance in energy homeostasis and promote weight loss.
- Clinical Trials: Multiple pivotal trials have provided evidence of sustained weight loss and improved metabolic parameters in patients, thereby reinforcing the products efficacy and safety profile.
2. Pipeline Developments:
- Rhythm is continuously expanding its pipeline to include other therapies targeting additional genetic obesity disorders. This includes investigational therapies in various stages of clinical trials aimed at different genetic targets.
Services
1. Patient Support Programs:
- Rhythm provides robust patient support services to help individuals navigate their treatment journey. These programs may include:
- Access Support: Helping patients understand their insurance benefits and access medication through financial assistance programs.
- Treatment Education: Offering educational resources for patients and healthcare providers about the use of Setmelanotide and its effects.
- Monitoring & Follow-up: Regular check-ins to monitor patient progress, potential side effects, and adherence to therapy.
2. Collaborations and Partnerships:
- The company may engage in collaborations with academic institutions, research organizations, and healthcare providers to further clinical research and improve treatment methodologies for rare genetic disorders.
3. Advocacy and Awareness:
- Rhythm actively participates in raising awareness about rare genetic disorders of obesity. They may collaborate with patient advocacy groups to ensure that those affected by these conditions have a voice in the research and development process.
Research and Development
- Rhythm invests significantly in research and development to explore new therapeutic approaches and enhance the understanding of the underlying mechanisms of obesity-related genetic disorders. This includes:
- Preclinical Studies: Investigating potential new compounds and their effects on various pathways involved in metabolism and energy balance.
- Clinical Research: Conducting Phase 1, 2, and 3 clinical trials to evaluate safety, efficacy, and long-term outcomes for existing and new therapies.
Market Position
- The company is positioned within a niche market focusing on rare genetic disorders, which sets it apart from traditional pharmaceutical companies that target broader therapeutic areas. The specialized nature of the market means Rhythm can address specific patient needs with tailored approaches.
Summary
Rhythm Pharmaceuticals, Inc. is at the forefront of addressing the complexities of rare genetic disorders of obesity through focused therapeutic development. With its flagship product Setmelanotide and an expanding pipeline, the company aims to meet the significant unmet needs of affected patients while providing comprehensive support services designed to improve patient experiences and outcomes.